Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides
about
Adenosine receptors as therapeutic targetsSignaling of the Human P2Y(1) Receptor Measured by a Yeast Growth Assay with Comparisons to Assays of Phospholipase C and Calcium Mobilization in 1321N1 Human Astrocytoma CellsMarking embryonic stem cells with a 2A self-cleaving peptide: a NKX2-5 emerald GFP BAC reporterEvaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure.Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position.Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor.Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptorThe crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors.Remote control of neuronal signaling.A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists.Probing the binding site of the A1 adenosine receptor reengineered for orthogonal recognition by tailored nucleosides.Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.Purine receptors: GPCR structure and agonist designExploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety.Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists.Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands.Chapter 13. A3 Adenosine Receptors.Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.Probing GPCR structure: adenosine and P2Y nucleotide receptors.Action of nucleosides and nucleotides at 7 transmembrane-spanning receptors.Neoceptors: reengineering GPCRs to recognize tailored ligandsOn the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor.The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.Synthesis of N6-substituted 3'-ureidoadenosine derivatives as highly potent agonists at the mutant A3 adenosine receptor.Structural Probing and Molecular Modeling of the A₃ Adenosine Receptor: A Focus on Agonist Binding.Nucleoside modification and concerted mutagenesis of the human A3 adenosine receptor to probe interactions between the 2-position of adenosine analogs and Gln167 in the second extracellular loop.Molecular modelling study of 2-phenylethynyladenosine (PEAdo) derivatives as highly selective A₃ adenosine receptor ligands.Engineering a GPCR-ligand pair that simulates the activation of D(2L) by Dopamine.Synthesis of 3'-amino-3'-deoxyguanosine and 3'-amino-3'-deoxyxyloguanosine monophosphate HepDirect prodrugs from guanosine.
P2860
Q24632095-E022FAF6-8DDC-4A69-860D-03148828D638Q25255546-0B439FAB-8CB2-4006-8424-5152EB9E8E2CQ27300999-C04F2071-3AA2-4CE3-A555-DE2E6B64CD2FQ30376612-2E0A16A8-DCC8-41FC-AD55-35A27A6745CAQ30424626-EBBA3282-96ED-4B73-94B4-23455BD2EBB7Q34118123-B070F1A2-3459-441D-A05F-7C3FDE38D8DAQ34190610-C0E2E1EA-F7C4-4E6A-A511-C022F44B29D0Q34313795-0CF9C8A4-21D7-4F13-ADD8-06B5320FC37FQ34858531-A3CD0E61-BE32-43CA-BD7C-6CEC779693B8Q35064892-BE344F08-B685-4BBF-BA17-0092A8FE9572Q35119322-C8D47066-EFC3-4CFD-B7A3-C53353525A9FQ36146803-3E1E9A36-B544-4496-8EA4-87B651ADA440Q36161738-9CA84263-5E95-4B09-BD73-2F3963986E0BQ36286344-248086AB-C218-4C62-B89A-70F20422FE14Q36316851-F3B16276-8DFA-4A23-93F4-C25A6E7A2D38Q36342342-9ABFA84E-16BA-453B-B022-93C800AE0F37Q36342540-E07B0BA2-5118-4B21-B795-952026972DC5Q36343219-26A02C09-5262-4BC3-946A-C7803A3A0A01Q36630298-07EA7EEF-1ED1-4662-A30E-E2FD433D142DQ36635966-6D09DD0B-708F-4BC6-96B1-C3D15399A26FQ36728991-26183A83-7C60-421A-8A1D-4E14BF3288DEQ36744266-1ED6D179-0571-4D6D-994C-C9137F020FEDQ37957791-2CD0FA28-5DFE-49F1-B21D-93A46250F1A6Q38503164-7D6AA4E0-E82A-4614-91A2-26EAFBB83587Q38911603-FD23939D-96EC-4BCE-BC9E-80F4BCEB92F7Q40324884-BC5B16AF-DC24-4DDA-8208-BC3A11C5A384Q40726425-D3182A82-A53B-4618-A2D2-D563E30D18E0Q42185342-13AEC725-1E46-45C9-907C-EDF922E493F8Q43150268-1E5B3CB6-E65A-4AC8-933D-505C61DE60AC
P2860
Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Neoceptor concept based on mol ...... for amine-modified nucleosides
@ast
Neoceptor concept based on mol ...... for amine-modified nucleosides
@en
Neoceptor concept based on mol ...... for amine-modified nucleosides
@nl
type
label
Neoceptor concept based on mol ...... for amine-modified nucleosides
@ast
Neoceptor concept based on mol ...... for amine-modified nucleosides
@en
Neoceptor concept based on mol ...... for amine-modified nucleosides
@nl
prefLabel
Neoceptor concept based on mol ...... for amine-modified nucleosides
@ast
Neoceptor concept based on mol ...... for amine-modified nucleosides
@en
Neoceptor concept based on mol ...... for amine-modified nucleosides
@nl
P2093
P2860
P356
P1476
Neoceptor concept based on mol ...... for amine-modified nucleosides
@en
P2093
K A Jacobson
P V Rompaey
S van Calenbergh
P2860
P304
P356
10.1021/JM010232O
P407
P50
P577
2001-11-22T00:00:00Z